Real World Evidence that Fluvoxamine Can Inhibit COVID-19 Preventing Hospitalization

Real World Evidence that Fluvoxamine Can Inhibit COVID-19 Preventing Hospitalization

Could the antidepressant medication fluvoxamine actually prevent individuals from severe disease progression associated with COVID-19? Apparently, data from a study reveals this could be the case which could lead to reduction in hospitalization. Led by a physician for Berkeley, California-based Golden Gates Fields and David Boulware, an infectious disease physician and scientists from the University of Minnesota Medical School in Minneapolis led what amounted to an observational, real world test” involving fluvoxamine after an incident when hundreds of race track workers became ill due to SARS-CoV-2 infections during Thanksgiving. Apparently, the evangelization of fluvoxamine by Steve Kirsch and his COVID-19 Early Treatment Fund found its way to Dr. Seftel. TrialSite has reported on Kirsch and his organization. The principal investigator for the Kirsch funded Washington University School of Medicine at St. Louis fluvoxamine trial presented on TrialSite Podcast. While the just reported real world data undoubtedly needs randomized controlled data to back up the  findings, some experts believe that these fresh observations coupled with preclinical research and other observational dat...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee